Introduction And Rationale
- Antimicrobial Resistance (AMR) poses a critical threat to vulnerable pediatric cohorts, particularly extreme premature neonates, primary immunodeficiency patients, and oncology patients.
- Unnecessary broad-spectrum antibiotic exposure disrupts the developing infant gut microbiome, causing dysbiosis linked to long-term adverse outcomes such as pediatric obesity, asthma, and atopic dermatitis.
- Antimicrobial Stewardship Programs (ASPs) aim to optimize drug selection, dose, route, and duration, accounting for dynamic, age-dependent pediatric pharmacokinetics and pharmacodynamics (PK/PD).
Core Elements Of Pediatric ASPs
- Effective ASPs require hospital leadership commitment, protected time, and a multidisciplinary team involving a pediatric infectious disease specialist, clinical pharmacist, microbiologist, and infection control nurse.
| Core Element | Intervention Strategy |
|---|---|
| Prospective Audit And Feedback (PAF) | Known as "Handshake" stewardship; involves direct engagement with prescribing pediatricians to suggest modifications or de-escalation based on culture sensitivities. |
| Formulary Restriction | Preauthorization is mandated for WHO "Reserve" category antibiotics (e.g., Colistin, Cefiderocol, Ceftazidime-avibactam) to restrict use to confirmed multi-drug resistant infections. |
| Tracking And Reporting | Tracking standardizes consumption data using "Days of Therapy" (DOT) per 1000 patient days to benchmark across PICUs and NICUs. |
| Clinical Decision Support Systems (CDSS) | Integrating pediatric-specific dosing guidelines and local antibiograms directly into the Electronic Medical Record (EMR). |
Diagnostic Stewardship And Innovations (2025-2026)
- Diagnostic stewardship ensures ordering the right test at the right time to guide therapeutic interventions.
- Rapid syndromic multiplex PCR (e.g., BioFire FilmArray) identifies over 20 specific respiratory or gastrointestinal pathogens in under an hour, facilitating rapid cessation of empiric antibiotics.
- Point-of-Care molecular platforms (Truenat, GeneXpert) provide rapid genotypic resistance data (mecA, blaNDM), allowing precise targeted therapy from the first dose.
- Advanced host-response biomarkers (transcriptomics) distinguish bacterial from viral immune responses with high sensitivity, providing an objective rationale to withhold antibiotics in virally infected infants.
- Artificial Intelligence predictive models analyze historical data and local antibiograms to suggest personalized empirical regimens.
- Automated Therapeutic Drug Monitoring (TDM) using Bayesian forecasting requires fewer blood draws, optimizing exposure for Vancomycin and Aminoglycosides while preventing nephrotoxicity and ototoxicity.
Recent Society Guidelines And National Policies
- IDSA Guidelines (2025-2026): The Surviving Sepsis Campaign mandates protocolized reassessment at 48 to 72 hours, promoting rapid de-escalation if blood cultures remain negative. Endorses a major shift toward short-course therapies (3-5 days) for uncomplicated community-acquired pneumonia (CAP) and UTIs.
- IAP Guidelines: Mandates empirical therapy based strictly on local antibiograms. Discourages irrational fixed-dose combinations (e.g., Ofloxacin + Ornidazole) for acute viral gastroenteritis. Promotes the WHO AWaRe (Access, Watch, Reserve) classification to prioritize "Access" group antibiotics.
- National Initiatives: The National Action Plan on Antimicrobial Resistance (NAP-AMR) enforces ASP establishment in all tertiary care hospitals. ASPs must be coupled with rigorous Infection Prevention and Control (IPC) programs utilizing hand hygiene and central line care bundles.